Updates are available Erratum dated 2016-11-16

Article History

Received: 29 March 2016

Accepted: 3 August 2016

First Online: 12 September 2016

Change Date: 19 October 2016

Change Type: Corrigendum

Change Details: In the version of this article initially published, author Mikael Ebbo was missing from the author list. The correct list is as follows: Frédéric Vély 1,2,20 , Vincent Barlogis 3,20 , Blandine Vallentin 3,20 , Bénédicte Neven 4–7,20 , Christelle Piperoglou 1,2 , Mikael Ebbo 1,8 , Thibaut Perchet 9,10 , Maxime Petit 9,10 , Nadia Yessaad 11 , Fabien Touzot 5,12 , Julie Bruneau 5,13 , Nizar Mahlaoui 4–7 , Nicolas Zucchini 14 , Catherine Farnarier 2 , Gérard Michel 3 , Despina Moshous 4–7 , Stéphane Blanche 4–7 , Arnaud Dujardin 15 , Hergen Spits 16 , Jörg H W Distler 17 , Andreas Ramming 17 , Capucine Picard 4–7,18 , Rachel Golub 9,10 , Alain Fischer 4–7,19,21 & Eric Vivier 1,2,21 . The correct affiliation list ends as follows: 8 APHM, Hôpital de la Timone, Service de Médecine Interne, Marseille, France. 9 Institut Pasteur, Unité de Lymphopoièse, INSERM, Paris, France. 10 Université Paris Diderot, Sorbonne Paris Cité, Cellule Pasteur, Paris, France. 11 MI-mAbs consortium, Aix-Marseille University, Marseille, France. 12 APHP, Hôpital Necker-Enfants Malades, Biotherapy Unit, Paris, France. 13 APHP, Hôpital Necker-Enfants Malades, Service d'anatomopathologie, Paris, France. 14 BD Biosciences, Le Pont-de-Claix, France. 15 Innate-Pharma, Marseille, France. 16 Academic Medical Center at the University of Amsterdam, Arizona Amsterdam, the Netherlands. 17 Department of Internal Medicine, Rheumatology & Immunology, University of Erlangen-Nuremberg, Erlangen, Germany. 18 APHP, Hôpital Necker-Enfants Malades, Study Center of Immunodeficiencies, Paris, France. 19 College de France, Paris, France. 20 These authors contributed equally to this work. 21 These authors jointly directed this work. The correct Author Contributions section ends as follows: "...and M.E., N.M., N.Z., C.F., G. M., D.M., S.B., A.D., H.S. and C. Pic. provided key expertise, reagents or samples." In addition, the description of patient C9 was incorrect in the text and legend for Figure 4b,d. The correct text (in the final paragraph of the fourth subsection of Results) is as follows: "In addition, NKp46 + ILCs and ILC2s were readily observed in tissues from patients treated with myeloablative HSCT, as illustrated by the analysis of skin biopsies from a patient with SCID who had mutation of RAG2 (C10) and was treated with myeloablative HSCT (Fig. 4b,d).... As a control, tissue-resident gut ILCs were observed in a patient with SCID who had mutation of RAG1 (C9) but was treated with 'pheno-related' HSCT (related donor with more than one compatible HLA haplotype but not genetically identical) under non-myeloablative conditions (Fig. 4b,d). The correct Figure 4b,d legend is as follows: "(b) Microscopy of tissue sections from patients who were treated with HSCT (stained as in a): duodenum (left) or colon (right) from C9 ( RAG1 mutation) and skin from C10 ( RAG2 mutation) (middle), at 15 months (C9) or 4 months (C10) after HSCT....(d) Microscopy of tissue sections from patients with SCID (colon from P5 and skin from P11 (as in a); colon from C9 and skin from C10 (as in b))...." Also, a label was missing under Figure 1d, far left; that should be labelled as 'Lin – CD127 + '. Finally, the description of lung NK cells in the final paragraph of Results was incorrect; that text should read as follows: "Similarly, lung NK cells (Lin – NKp46 + NK1.1 + CD127 – ) underwent reconstitution...." These errors have been corrected in the PDF and HTML versions of this article.

Competing interests

: E.V. is the cofounder of and a shareholder in Innate Pharma.